Literature DB >> 26550417

Expression of Toll-like receptor 4 in ovarian serous adenocarcinoma and correlation with clinical stage and pathological grade.

Xue-Zhen Luo1, Qi-Zhi He2, Kai Wang3.   

Abstract

Toll-like receptor 4 (TLR4) plays an essential role in adaptive and innate immunity, and its expression has been described in various tumors. This study aimed to examine the expression of TLR4 in serous tumors and to evaluate its correlation to clinicopathological parameters. The expression of TLR4 was immunohistochemically examined in 63 species of normal ovarian epithelia and 336 species of serous epithelial lesions. Moreover, the association between TLR4 expression and various clinicopathologic features was assessed. The expression intensity of TLR4 in benign and borderline to malignant ovarian tumours showed a gradual rising trend. We identified positive correlations between TLR4 expression levels and both FIGO stage and pathological stage. In serous adenocarcinoma, TLR4 expression levels were significantly associated with chemoresistance. There was no relationship between the expression of TLR4 and the patient's age or pretreatment serum CA125 levels. Our data suggest that TLR4 might stimulate serous ovarian carcinoma initiation and progression. TLR4 expression is correlated with poor chemoresponse, which has important implications for the development of new therapeutic strategies for drug-resistant ovarian cancer.

Entities:  

Keywords:  Serous ovarian carcinoma; immunohistochemistry; toll-like receptor 4

Year:  2015        PMID: 26550417      PMCID: PMC4613102     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  Ovarian cancer.

Authors:  Gordon C Jayson; Elise C Kohn; Henry C Kitchener; Jonathan A Ledermann
Journal:  Lancet       Date:  2014-04-21       Impact factor: 79.321

2.  Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer.

Authors:  Zahava Berkowitz; Sun Hee Rim; Lucy A Peipins
Journal:  Cancer Epidemiol       Date:  2010-07-31       Impact factor: 2.984

3.  Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas.

Authors:  Qi-Zhi He; Xun-Zhen Luo; Kai Wang; Qian Zhou; Hong Ao; Yan Yang; Shu-Xia Li; Ying Li; Hui-Ting Zhu; Tony Duan
Journal:  Cell Physiol Biochem       Date:  2014-01-24

Review 4.  Dose-dense approaches to ovarian cancer treatment.

Authors:  Noriyuki Katsumata
Journal:  Curr Treat Options Oncol       Date:  2015-05

Review 5.  Ovarian cancer: etiology, risk factors, and epidemiology.

Authors:  Jessica Hunn; Gustavo C Rodriguez
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 6.  Inflammation and ovarian cancer.

Authors:  Antonio Macciò; Clelia Madeddu
Journal:  Cytokine       Date:  2012-02-19       Impact factor: 3.861

7.  Expression of nestin in ovarian serous cancer and its clinicopathologic significance.

Authors:  Q-Z He; X-Z Luo; Q Zhou; K Wang; S-X Li; Y Li; H-T Zhu; T Duan
Journal:  Eur Rev Med Pharmacol Sci       Date:  2013-11       Impact factor: 3.507

Review 8.  Toll-like receptors, tissue injury, and tumourigenesis.

Authors:  Savvas Ioannou; Michael Voulgarelis
Journal:  Mediators Inflamm       Date:  2010-09-14       Impact factor: 4.711

Review 9.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

10.  TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.

Authors:  M Szajnik; M J Szczepanski; M Czystowska; E Elishaev; M Mandapathil; E Nowak-Markwitz; M Spaczynski; T L Whiteside
Journal:  Oncogene       Date:  2009-12-10       Impact factor: 9.867

  10 in total
  8 in total

1.  Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.

Authors:  Bahareh Kashani; Zahra Zandi; Mohammad Reza Karimzadeh; Davood Bashash; Ali Nasrollahzadeh; Seyed H Ghaffari
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

Review 2.  TLR4 Polymorphisms and Expression in Solid Cancers.

Authors:  Nilesh Pandey; Alex Chauhan; Neeraj Jain
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

3.  The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.

Authors:  Zheng Li; Matthew S Block; Robert A Vierkant; Zachary C Fogarty; Stacey J Winham; Daniel W Visscher; Kimberly R Kalli; Chen Wang; Ellen L Goode
Journal:  Tumour Biol       Date:  2016-07-26

4.  Osteopontin is involved in TLR4 pathway contributing to ovarian cancer cell proliferation and metastasis.

Authors:  Cong Xu; Hua Li; Miao Yin; Tao Yang; Liguo An; Guiwen Yang
Journal:  Oncotarget       Date:  2017-10-12

5.  An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.

Authors:  Qing Kay Li; Punit Shah; Yuan Tian; Yingwei Hu; Richard B S Roden; Hui Zhang; Daniel W Chan
Journal:  Clin Proteomics       Date:  2017-05-10       Impact factor: 3.988

6.  Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer.

Authors:  Chel Hun Choi; Tae Heung Kang; Joon Seon Song; Young Seob Kim; Eun Joo Chung; Kris Ylaya; Seokho Kim; Sang Seok Koh; Joon-Yong Chung; Jae-Hoon Kim; Stephen M Hewitt
Journal:  Sci Rep       Date:  2018-08-15       Impact factor: 4.379

7.  Activation of the TLR4/MyD88 signaling pathway contributes to the development of human hepatocellular carcinoma via upregulation of IL-23 and IL-17A.

Authors:  Yuming Kang; Guoai Su; Jianmin Sun; Yanli Zhang
Journal:  Oncol Lett       Date:  2018-04-26       Impact factor: 2.967

8.  The Toll-like Receptor 4 Polymorphism Asp299Gly Is Associated with an Increased Risk of Ovarian Cancer.

Authors:  Katarzyna D Kania; Daria Haręża; Jacek R Wilczyński; Miłosz Wilczyński; Dariusz Jarych; Andrzej Malinowski; Edyta Paradowska
Journal:  Cells       Date:  2022-10-05       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.